Nothing Special   »   [go: up one dir, main page]

Lane et al., 1987 - Google Patents

Antithrombin III Northwick Park: demonstration of an inactive high MW complex with increased affinity for heparin

Lane et al., 1987

Document ID
5676143100338298723
Author
Lane D
Flynn A
Ireland H
Erdjument H
Samson D
Howarth D
Thompson E
Publication year
Publication venue
British journal of haematology

External Links

Snippet

It has been shown previously that antithrombin III Northwick Park has reduced ability to inactivate thrombin and is characterized by an additional anodal component on crossed immunoelectrophoresis (Howarth et al. 1985). We have applied plasma from an affected …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Similar Documents

Publication Publication Date Title
Tuszynski et al. Isolation and characterization of antistasin. An inhibitor of metastasis and coagulation.
Schwartz et al. The fibrinogenolytic activity of purified tryptase from human lung mast cells.
Lijnen et al. Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma.
Pratt et al. Heparin binding to protein C inhibitor.
Kelly et al. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin.
Lane et al. Antithrombin III Northwick Park: demonstration of an inactive high MW complex with increased affinity for heparin
AU634730B2 (en) Antithrombotic composition
Yamagishi et al. Purification and biological property of heparin cofactor II: Activation of heparin cofactor II and antithrombin III by dextran sulfate and various glycosaminoglycans
Lijnen et al. On the Rolw of the Carbohydrate Side Chains of Human Plasminogen in Its Interaction with α2‐Antiplasmin and Fibrin
Martinez et al. Functional and metabolic properties of human asialofibrinogen
Vinazzer Clinical use of antithrombin III concentrates
RU2153506C2 (en) Dermatan sulfate or its salt, antithrombotic agents, method of prophylaxis and treatment of thrombosis, method of prophylaxis or treatment of disseminated intravascular coagulation syndrome, method of myocardium infarction treatment
US4446126A (en) Antithrombin-heparin complex and method for its production
Tollefsen et al. Modulation of heparin cofactor II activity by histidine-rich glycoprotein and platelet factor 4.
Jaques et al. Pharmacodynamics and clinical effectiveness of heparin
CA1240264A (en) Covalently bound heparin-antithrombin iii complex
Vogel et al. Correlation of in vivo and in vitro inhibition of thrombin by plasma inhibitors
Shirk et al. Arterial smooth muscle cell heparan sulfate proteoglycans accelerate thrombin inhibition by heparin cofactor II
Wolf et al. Antithrombin Milano: a new variant with monomeric and dimeric inactive antithrombin III
Erdjument et al. Antithrombin Milano, single amino acid substitution at the reactive site, Arg393 to Cys
Budzynski et al. Determination of human fibrinopeptide A by radioimmunoassay in purified systems and in the blood
Lane et al. Antithrombin III Glasgow: a variant with increased heparin affinity and reduced ability to inactivate thrombin, associated with familial thrombosis
Feinman et al. Kinetics of the reaction of thrombin and α2-macroglobulin
Pöschel et al. Pharmacodynamics and pharmacokinetics of polyethylene glycol-hirudin in patients with chronic renal failure
EP0048898B1 (en) Method for the production of an antithrombin-heparin complex and pharmaceutical compositions containing the complex